Shanghai Ark Biopharmaceutical Co., Ltd.
We are a biopharmaceutical company focused on the discovery and development of therapeutics addressing unmet medical needs in respiratory and lung diseases. With a product portfolio covering full disease cycle and patient segmentations, our drug candidates address a spectrum of acute and chronic respiratory and lung diseases that currently lack effective treatments.
  • AK0529
    The first non-oncology drug designated breakthrough therapy by the NMPA, AK0529 is the first respiratory syncytial virus (RSV) drug worldwide to enter phase III clinical trial in hospitalized infants and young children and is currently in phase III registration trial in pediatric patients.
  • AK3280
    Designed as the second generation pirfenidone with a potentially superior efficacy and safety profile, AK3280 is a phase II-ready drug with broad anti-fibrotic effect to potentially treat lung and liver fibrosis, such as IPF.
    Our pipeline also includes several IND-enabling or pre-clinical stage programs developed in-house or collaborated with domestic and global partners for hepatitis B, chronic obstructive pulmonary disease (COPD), and fibrotic diseases.

We adhere to and are driven by our mission for scientific innovation. We strive to serve the unmet medical needs of global patients, to create a flourish work environment for our employees, and to reward our investors, collaborators, and the community.

  • Home
  • Tel
  • Top